<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840317</url>
  </required_header>
  <id_info>
    <org_study_id>Senl_1904A &amp; Senl_1904B CAR-T</org_study_id>
    <nct_id>NCT03840317</nct_id>
  </id_info>
  <brief_title>Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia</brief_title>
  <official_title>Randomized, Parallel-arm, Controlled Trial of Senl_1904A and Senl_1904B Autologous CAR-T Cell Injections in the Treatment of Relapsed and Refractory Acute B Lymphocytic Leukemia(r/r B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two&#xD;
      different chimeric antigen receptor T cell immunotherapies (Senl_1904A and Senl_1904B)&#xD;
      targeting cluster of differentiation antigen 19 （CD19） in the treatment of Acute lymphocytic&#xD;
      Leukemia. A total of 20 patients are planned to be enrolled following up half a year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CARs consist of an anti-CD19 single-chain variable fragment（scFv） that was derived from&#xD;
      the FMC63 mouse hybridoma, a portion of the human CD137（4-1BB） molecule, and the&#xD;
      intracellular component of the human CD3ζ molecule. Autologous T cells will be gene&#xD;
      engineered with the CAR gene using a lentivirus vector. Compared to Senl_1904A, Senl_1904B&#xD;
      has a higher and more stable transfection efficiency and secretes lower levels of cytokines&#xD;
      in functional assays, thus having the potential to significantly reduce the incidence of&#xD;
      serious adverse events while ensuring the same complete response rate. Prior to T cell&#xD;
      infusion, the patients will be subjected to preconditioning treatment. After T cell infusion,&#xD;
      the patients will be evaluated for one month after infusion for adverse reactions and&#xD;
      efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor load</measure>
    <time_frame>up to one month</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR T cell expansion</measure>
    <time_frame>up to one month</time_frame>
    <description>The percentage of CAR-T cells (CAR+/CD3+ T cells) in the bone marrow samples, quantified by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR T cell persistence</measure>
    <time_frame>up to one month</time_frame>
    <description>The method to detect CAR-T cell persistence is by determining the exact copies of CAR per ug DNA in BM through quantitative polymerase chain reaction（qPCR）</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Senl_1904A CD19 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Senl_1904B CD19 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous CD19-targeting CAR T cells</intervention_name>
    <description>Autologous CD19-targeting CAR T cells</description>
    <arm_group_label>Senl_1904A CD19 CAR-T</arm_group_label>
    <arm_group_label>Senl_1904B CD19 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute lymphocytic leukemia who voluntarily signed informed consent and&#xD;
             met the following criteria:&#xD;
&#xD;
               1. Patients with relapsed and refractory acute B lymphocytic leukemia with any of&#xD;
                  the following:&#xD;
&#xD;
                    1. Recurrence after remission by chemotherapy or autologous stem cell&#xD;
                       transplantation (including B-ALL patients with bone marrow recurrence of&#xD;
                       morphology and recurrence of micro-residual );&#xD;
&#xD;
                    2. Primary B-ALL patients who cannot be completely relieved by repeated&#xD;
                       chemotherapy twice or more;&#xD;
&#xD;
                    3. High-risk initial onset B-ALL patients not completely relieved after 1 or 2&#xD;
                       times of chemotherapy but not suitable for re-chemotherapy ;&#xD;
&#xD;
               2. Tumor cells confirmed CD19 positive by Flow cytometry (FCM)&#xD;
&#xD;
               3. For B-ALL patients with simple extramedullary recurrence , there must be at least&#xD;
                  one evaluable lesion;&#xD;
&#xD;
               4. Eastern Cooperative Oncology Group (ECOG) ≤ 2 points;&#xD;
&#xD;
               5. Age 3 - 65 years old;&#xD;
&#xD;
               6. The bone marrow tumor load value (morphology) &gt; 5% at the time of enrollment;&#xD;
&#xD;
               7. The main organ function needs to meet the above conditions: cardiac ultrasound or&#xD;
                  multiple gated image acquisition analysis （MUGA） scan indicate the cardiac&#xD;
                  ejection fraction is ≥50% , and there is no obvious abnormality in the&#xD;
                  electrocardiogram; blood oxygen saturation≥90%; creatinine ≤1.6mg/dl; alanine&#xD;
                  amino transferase (ALT) and Aspartate transaminase (AST)≤3 times normal range,&#xD;
                  total bilirubin（TBil） ≤2.0mg/dl;&#xD;
&#xD;
               8. The expected survival time is longer than 3 months;&#xD;
&#xD;
               9. The pregnancy test for women of childbearing age must be negative; Subjects with&#xD;
                  a pregnancy plan must agree to take contraception before the enrollment study and&#xD;
                  after the study lasts for one year; if the subject is pregnant or suspects of&#xD;
                  pregnancy, the investigator should be notified immediately&#xD;
&#xD;
              10. An informed consent form is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Severe cardiac insufficiency; 2) A history of severe pulmonary dysfunction; 3)&#xD;
             Combined with other malignant tumors; 4) Combined with serious infections or&#xD;
             persistent infection and cannot be effectively controlled; 5) Combined with metabolic&#xD;
             diseases (except DM); 6) Combined with severe autoimmune diseases or congenital immune&#xD;
             defects; 7) Active hepatitis (HBV DNA or HCVRNA detection positive); 8) HIV infection&#xD;
             or syphilis infection; 9) A history of severe allergies to biological products&#xD;
             (including antibiotics); 10) Subjects with recurrence after allogeneic hematopoietic&#xD;
             stem cell transplantation 11) chronic lymphocytic leukemia（CLL） /myeloproliferative&#xD;
             neoplasms with acute lymphoid transformation or CLL transform to ALL ; 12) Any drug&#xD;
             that has been used against graft-versus-host disease（GVHD） for nearly 4 weeks, such as&#xD;
             methotrexate or other chemotherapeutic drugs, mycophenolate mofetil, immunosuppressive&#xD;
             antibodies, etc.; 13) Subjects who have received any anti-CD19 medication; 14)&#xD;
             Subjects who have used anti-cluster of differentiation antigen 20（CD20） drugs (such as&#xD;
             rituximab) for nearly 4 weeks; 15) Subjects who have participated in any other&#xD;
             clinical drug trials in the past six months; 16) Female patients who are pregnant and&#xD;
             lactating, or have a pregnancy plan within 12 months; 17) The investigator believes&#xD;
             that it may increase the risk of the subject or interfere with the outcome of the test&#xD;
             (with a history of severe mental illness, drug abuse and history of addiction).&#xD;
&#xD;
        Exit criteria：&#xD;
&#xD;
          1. The subjects request to withdraw from the study before CAR-T infusion&#xD;
&#xD;
          2. The subjects seriously violate the protocol&#xD;
&#xD;
          3. Before CAR-T infusion, the following indicators are still abnormal after treatment:&#xD;
&#xD;
             Platelets &lt;20x10^9/L, hemoglobin ≤80g/L, peripheral finger oxygen &lt;90%, AST / ALT /&#xD;
             alkaline phosphatase（ALP） ≥ 2.5 upper limits of normal（ULN）, total bilirubin ≥ 1.5ULN&#xD;
             , creatinine clearance rate &lt;70ml / min, left ventricular ejection fraction &lt;50%, the&#xD;
             researcher judged that the test needs to be terminated early;&#xD;
&#xD;
          4. The therapeutic dose of steroids was not stopped within 72 hours prior to CAR-T&#xD;
             infusion and the investigator determined that the trial needs to be terminated .&#xD;
             However, the following physiologically acceptable doses of steroids are permissible:&#xD;
             hydrocortisone or equivalent &lt;6-12 mg/m2/day ;&#xD;
&#xD;
          5. Not enough T cells for manufacture standard CAR-T cells&#xD;
&#xD;
          6. Other serious adverse events occurred&#xD;
&#xD;
          7. MRD become negative after preconditioning regiment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua Lu, PhD&amp;MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

